-
-
-
-
-
-
-
Appili Therapeutics announces C$750,000 private placement
-
-
-
-
-
-
-
Appili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025
-
-
-
-
-
-
-
Aditxt Subsidiary Adimune to Ship Drug Substances for Final Drug Product Formulation of ADI-100 Ahead of Planned Clinical Trials in Type 1 Diabetes and Psoriasis in Germany, and Stiff Person Syndrome
-
-
-
-
-
-
-
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025
-
-
-
-
-
-
-
Sylvia Hermina Joins Aditxt’s Board of Directors, Elevating Leadership with Broader Perspectives
-
-
-
-
-
-
-
Aditxt Delivers Shareholder Update and 2024 Year-End Plan
-
-
-
-
-
-
-
Aditxt Subsidiary Pearsanta Submits a Grant Application Seeking to Advance Clinical Trials for Mitomic® Prostate Test, Targeting Early Detection in High-Risk Patients
-
1,154,849 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

